For decades, endometriosis has been underfunded, misunderstood, and undertreated. New science is changing that. Here is why the $220 billion endometriosis market represents one of the most compelling opportunities in medicine today.

Sur180 Therapeutics CEO Dr. Annelyn Torres-Reverón was featured on Notiséis WIPR, discussing the company’s mission and its novel non-hormonal approach to treating endometriosis.